State of PD-L1 and PD-1 screening and therapy in NSCLC
Lung cancer is still the leading cause of death among all malignancies worldwide. The development of targeted therapies against driver mutations such as EGFR, ALK1, ROS1 and BRAF have led to a significant improvement in patient progression free survival and to a benefit in quality of life of patien...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
DiagnomX
2018-04-01
|
| Series: | Diagnostic Pathology |
| Online Access: | http://www.diagnosticpathology.eu/content/index.php/dpath/article/view/262 |